Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 551 participants.

Also called NCT06353347

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 551 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06353347
Other papers using this trial's data
  • HTD1801 in Combination with Metformin for Type 2 Diabetes NEJM evidence, 2026-07 DOI, PubMed 42251702

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06353347. Randomized; double masking; primary purpose treatment. Start 2023-11-13 (actual); primary completion 2024-12-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
Acronym
SYMPHONY-2
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
HTD1801
Intervention (Drug)
Placebo
Lead sponsor
Shenzhen HighTide Biopharmaceutical Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06353347
Content hash
6efe4ba0f9645a0ee8b1ab1a06820f0cbe68dd464d501269f7821d3b56cceeab